Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food-Effect Study of H3B-6527 in Healthy Subjects
NCT03424577Phase 1Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Dec 2017
- Primary completion
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of H3B-6527 in hepatocellular carcinoma (HCC) (2 arms), sponsored by Eisai Co., Ltd. Primary endpoints: Mean area under the plasma-concentration time curve from time 0 through the last measurable concentration at Day 5, Time of maximum observed plasma concentration at Day 5 and 1 more. Started Dec 2017; status: completed.
02
Drugs
H3B-6527
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03424577.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03424577.